Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models | GLMD Stock NewsStockTitan·1 day ago, 12:15 AMGLMD-1.85%
Galmed Pharmaceuticals to execute 1-for-8 reverse share split Aug. 19, 2026PUBT·Aug 14 at 03:35 PMGLMD-1.85%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Aug 3 at 07:06 AMGLMD-1.85%AMIX-6.57%
Biotech's 2026 Reality Check: Who's Actually Delivering Beyond the Hype?Global Report·Aug 1 at 04:14 AMIBRX+4.62%ABCL-1.58%
The Market's Junk Drawer: Diapers, Jets, and AI's Hidden BackboneGlobal Report·Jul 31 at 04:22 AMGLMD-1.85%HNST-2.89%
Berkshire's Housing Buyout and Cardinal Health's M&A Blitz Headline Q3 DealmakingGlobal Report·Jul 30 at 04:14 AMVNET+4.21%VKTX+1.33%
Safran and United Rentals Raise 2026 Forecasts as M&A Activity Reshapes Mid-Cap LandscapesGlobal Report·Jul 29 at 04:19 AMORCL-D-1.08%GLMD-1.85%
07:00 ETGalmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Marketprnewswire·Jul 28 at 06:01 AMGLMD-1.85%
